{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T13:19:31Z","timestamp":1787318371505,"version":"build-2736575974"},"reference-count":100,"publisher":"Deutscher Arzte-Verlag GmbH","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.3238\/arztebl.m2022.0254","type":"journal-article","created":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T05:10:25Z","timestamp":1660108225000},"source":"Crossref","is-referenced-by-count":19,"title":["Multimodal treatment of rectal cancer"],"prefix":"10.3238","author":[{"given":"Michael","family":"Ghadimi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus","family":"R\u00f6del","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"Hofheinz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Flebbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marian","family":"Grade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"11437","published-online":{"date-parts":[[2022,8,22]]},"reference":[{"key":"10.3238\/arztebl.m2022.0254_ref1","doi-asserted-by":"crossref","unstructured":"Smith JJ, Garcia-Aguilar J: Advances and challenges in treatment of locally advanced rectal cancer. J Clin Oncol 2015; 33: 1797–808.","DOI":"10.1200\/JCO.2014.60.1054"},{"key":"10.3238\/arztebl.m2022.0254_ref2","doi-asserted-by":"crossref","unstructured":"Glynne-Jones R, Wyrwicz L, Tiret E, et al.: Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017; 28.","DOI":"10.1093\/annonc\/mdx224"},{"key":"10.3238\/arztebl.m2022.0254_ref3","unstructured":"AWMF: S3-Leitlinie Kolorektales Karzinom. https:\/\/www.awmf.org\/uploads\/tx_szleitlinien\/021-007OLl_S3_Kolorektales-Karzinom-KRK_2019-01.pdf (last accessed on 27 February 2022)."},{"key":"10.3238\/arztebl.m2022.0254_ref4","unstructured":"Benson AB, Venook AP, Al-Hawary MM, et al.: NCCN guidelines insights: rectal cancer, Version 6.2020. J Natl Compr Canc Netw 2020; 18: 806–15."},{"key":"10.3238\/arztebl.m2022.0254_ref5","doi-asserted-by":"crossref","unstructured":"Keller DS, Berho M, Perez RO, Wexner SD, Chand M: The multidisciplinary management of rectal cancer. Nat Rev Gastroenterol Hepatol 2020; 17: 414–29.","DOI":"10.1038\/s41575-020-0275-y"},{"key":"10.3238\/arztebl.m2022.0254_ref6","doi-asserted-by":"crossref","unstructured":"Deschner BW, VanderWalde NA, Grothey A, Shibata D: Evolution and current status of the multidisciplinary management of locally advanced rectal cancer. JCO Oncol Pract 2021; 17: 383–402.","DOI":"10.1200\/OP.20.00885"},{"key":"10.3238\/arztebl.m2022.0254_ref7","doi-asserted-by":"crossref","unstructured":"Balyasnikova S, Brown G: Optimal imaging strategies for rectal cancer staging and ongoing management. Curr Treat Options Oncol 2016; 17: 016–0403.","DOI":"10.1007\/s11864-016-0403-7"},{"key":"10.3238\/arztebl.m2022.0254_ref8","doi-asserted-by":"crossref","unstructured":"Hunter C, Brown G: Pre-operative staging of rectal cancer: a review of imaging techniques. Expert Rev Gastroenterol Hepatol 2016; 10: 1011–25.","DOI":"10.1080\/17474124.2016.1179577"},{"key":"10.3238\/arztebl.m2022.0254_ref9","unstructured":"Attenberger U, R\u00f6del C, Ghadimi M, et al.: [Prerequisites of magnetic resonance imaging for treatment planning in locally advanced rectal cancer – Interdisciplinary recommendations]. Z Gastroenterol 2020; 58: 577–82."},{"key":"10.3238\/arztebl.m2022.0254_ref10","doi-asserted-by":"crossref","unstructured":"Keller DS: Staging of locally advanced rectal cancer beyond TME. Clin Colon Rectal Surg 2020; 33: 258–67.","DOI":"10.1055\/s-0040-1713743"},{"key":"10.3238\/arztebl.m2022.0254_ref11","doi-asserted-by":"crossref","unstructured":"Stelzner S, Fichtner-Feigl S, Kahlke V, et al.: [Standardization of preoperative locoregional staging in rectal cancer with MRI]. Chirurg 2021; 92: 482–4.","DOI":"10.1007\/s00104-021-01411-y"},{"key":"10.3238\/arztebl.m2022.0254_ref12","doi-asserted-by":"crossref","unstructured":"Grade M, Flebbe H, Ghadimi BM: [Evidence-based surgery of rectal cancer]. Chirurg 2019; 90: 387–97.","DOI":"10.1007\/s00104-019-0802-y"},{"key":"10.3238\/arztebl.m2022.0254_ref13","doi-asserted-by":"crossref","unstructured":"Swedish Rectal Cancer Trial; Cedermark B, Dahlberg M, Glimelius B, P\u00e5hlman L, Rutqvist LE, Wilking N: Improved survival with preoperative radiotherapy in resectable rectal cancer. N Engl J Med 1997; 336: 980–7.","DOI":"10.1056\/NEJM199704033361402"},{"key":"10.3238\/arztebl.m2022.0254_ref14","doi-asserted-by":"crossref","unstructured":"Kapiteijn E, Marijnen CA, Nagtegaal ID, et al.: Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 2001; 345: 638–46.","DOI":"10.1056\/NEJMoa010580"},{"key":"10.3238\/arztebl.m2022.0254_ref15","doi-asserted-by":"crossref","unstructured":"Sauer R, Becker H, Hohenberger W, et al.: Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004; 351: 1731–40.","DOI":"10.1056\/NEJMoa040694"},{"key":"10.3238\/arztebl.m2022.0254_ref16","doi-asserted-by":"crossref","unstructured":"Sauer R, Liersch T, Merkel S, et al.: Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO\/ARO\/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol 2012; 30: 1926–33.","DOI":"10.1200\/JCO.2011.40.1836"},{"key":"10.3238\/arztebl.m2022.0254_ref17","doi-asserted-by":"crossref","unstructured":"Fokas E, Allg\u00e4uer M, Polat B, et al.: Randomized phase II trial of chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for locally advanced rectal cancer: CAO\/ARO\/AIO-12. J Clin Oncol 2019; 37: 3212–22.","DOI":"10.1200\/JCO.19.00308"},{"key":"10.3238\/arztebl.m2022.0254_ref18","doi-asserted-by":"crossref","unstructured":"Fokas E, Schlenska-Lange A, Polat B, et al.: Chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for patients with locally advanced rectal cancer: long-term results of the CAO\/ARO\/AIO-12 randomized clinical trial. JAMA Oncol 2022; 8: 20.","DOI":"10.1001\/jamaoncol.2021.5445"},{"key":"10.3238\/arztebl.m2022.0254_ref19","unstructured":"Bahadoer RR, Dijkstra EA, van Etten B, et al.: Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Lancet Oncol 2021; 22: 29–42."},{"key":"10.3238\/arztebl.m2022.0254_ref20","doi-asserted-by":"crossref","unstructured":"Conroy T, Bosset JF, Etienne PL, et al.: Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 2021; 22: 702–15.","DOI":"10.1016\/S1470-2045(21)00079-6"},{"key":"10.3238\/arztebl.m2022.0254_ref21","unstructured":"Garcia-Aguilar J, Patil S, Gollub MJ, et al.: Organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy. J Clin Oncol 2022; 28:JCO2200032."},{"key":"10.3238\/arztebl.m2022.0254_ref22","doi-asserted-by":"crossref","unstructured":"Guetz GD, Landre T, Larrouy A, et al.: Is there a benefit of oxaliplatin in neoadjuvant treatment of locally advanced rectal cancer? An updated meta-analysis. J Clin Oncol 2020; 38: (Suppl) 4098.","DOI":"10.1200\/JCO.2020.38.15_suppl.4098"},{"key":"10.3238\/arztebl.m2022.0254_ref23","doi-asserted-by":"crossref","unstructured":"Fontana E, Zichi C, Smyth EC, et al.: Neoadjuvant chemoradiation (CRT) for locally advanced rectal cancer (LARC) with or without oxaliplatin (OX): individual patient data (IPD) meta-analysis of three randomized controlled trials (RCTs) with subgroup analyses of age cohorts. J Clin Oncol 2020; 38: (Suppl) 4074.","DOI":"10.1200\/JCO.2020.38.15_suppl.4074"},{"key":"10.3238\/arztebl.m2022.0254_ref24","unstructured":"AIO, ACO, ARO: Konsensierte Stellungnahme der AIO, der ACO und der ARO zur neoadjuvanten Therapie beim Rektumkarzinom. www.aio-portal.de\/stellungnahmen.html?file=files\/content\/studien\/stellungnahmen\/2020\/Stellungnahme_AIO_ACO_ARO_Rektumkarzinom% 20_%2007_2020.pdf&cid=142 (last accessed on 29 July 2022)."},{"key":"10.3238\/arztebl.m2022.0254_ref25","doi-asserted-by":"crossref","unstructured":"MERCURY Study Group: Extramural depth of tumor invasion at thin-section MR in patients with rectal cancer: results of the MERCURY study. Radiology 2007; 243: 132–9.","DOI":"10.1148\/radiol.2431051825"},{"key":"10.3238\/arztebl.m2022.0254_ref26","doi-asserted-by":"crossref","unstructured":"Taylor FG, Quirke P, Heald RJ, et al.: Preoperative magnetic resonance imaging assessment of circumferential resection margin predicts disease-free survival and local recurrence: 5-year follow-up results of the MERCURY study. J Clin Oncol 2014; 32: 34–43.","DOI":"10.1200\/JCO.2012.45.3258"},{"key":"10.3238\/arztebl.m2022.0254_ref27","doi-asserted-by":"crossref","unstructured":"Taylor FG, Quirke P, Heald RJ, et al.: Preoperative high-resolution magnetic resonance imaging can identify good prognosis stage I, II, and III rectal cancer best managed by surgery alone: a prospective, multicenter, European study. Ann Surg 2011; 253: 711–9.","DOI":"10.1097\/SLA.0b013e31820b8d52"},{"key":"10.3238\/arztebl.m2022.0254_ref28","doi-asserted-by":"crossref","unstructured":"Battersby NJ, How P, Moran B, et al.: Prospective validation of a low rectal cancer magnetic resonance imaging staging system and development of a local recurrence risk stratification model: the MERCURY II study. Ann Surg 2016; 263: 751–60.","DOI":"10.1097\/SLA.0000000000001193"},{"key":"10.3238\/arztebl.m2022.0254_ref29","doi-asserted-by":"crossref","unstructured":"Ruppert R, Kube R, Strassburg J, et al.: Avoidance of overtreatment of rectal cancer by selective chemoradiotherapy: results of the optimized surgery and MRI-based multimodal therapy trial. J Am Coll Surg 2020; 231: 413–25.","DOI":"10.1016\/j.jamcollsurg.2020.06.023"},{"key":"10.3238\/arztebl.m2022.0254_ref30","doi-asserted-by":"crossref","unstructured":"Kreis ME, Ruppert R, Kube R, et al.: MRI-based use of neoadjuvant chemoradiotherapy in rectal carcinoma: surgical quality and histopathological outcome of the OCUM trial. Ann Surg Oncol 2020; 27: 417–27.","DOI":"10.1245\/s10434-019-07696-y"},{"key":"10.3238\/arztebl.m2022.0254_ref31","doi-asserted-by":"crossref","unstructured":"Lauscher JC, Schineis CHW, Weixler B, Kreis ME: [The importance of radiotherapy in rectal cancer-an update from a surgeon‘s perspective]. Chirurg 2021; 92: 591–8.","DOI":"10.1007\/s00104-021-01414-9"},{"key":"10.3238\/arztebl.m2022.0254_ref32","doi-asserted-by":"crossref","unstructured":"Habr-Gama A, Perez RO, Nadalin W, et al.: Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Ann Surg 2004; 240: 711–7.","DOI":"10.1097\/01.sla.0000141194.27992.32"},{"key":"10.3238\/arztebl.m2022.0254_ref33","doi-asserted-by":"crossref","unstructured":"Maas M, Beets-Tan RG, Lambregts DM, et al.: Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer. J Clin Oncol 2011; 29: 4633–40.","DOI":"10.1200\/JCO.2011.37.7176"},{"key":"10.3238\/arztebl.m2022.0254_ref34","doi-asserted-by":"crossref","unstructured":"Marijnen CA: Organ preservation in rectal cancer: have all questions been answered? Lancet Oncol 2015; 16: 70398–5.","DOI":"10.1016\/S1470-2045(14)70398-5"},{"key":"10.3238\/arztebl.m2022.0254_ref35","doi-asserted-by":"crossref","unstructured":"Nelson H, Machairas N, Grothey A: Evidence in favor of standard surgical treatment for rectal cancer. JAMA Oncol 2017; 3: 885–6.","DOI":"10.1001\/jamaoncol.2016.5397"},{"key":"10.3238\/arztebl.m2022.0254_ref36","doi-asserted-by":"crossref","unstructured":"Smith JJ, Paty PB, Garcia-Aguilar J: Watch and wait in rectal cancer or more wait and see? JAMA Surg 2020; 155: 657–8.","DOI":"10.1001\/jamasurg.2020.0226"},{"key":"10.3238\/arztebl.m2022.0254_ref37","doi-asserted-by":"crossref","unstructured":"Fokas E, Appelt A, Glynne-Jones R, et al.: International consensus recommendations on key outcome measures for organ preservation after (chemo)radiotherapy in patients with rectal cancer. Nat Rev Clin Oncol 2021; 18: 805–16.","DOI":"10.1038\/s41571-021-00538-5"},{"key":"10.3238\/arztebl.m2022.0254_ref38","doi-asserted-by":"crossref","unstructured":"Kastner C, Petritsch B, Reibetanz J, Germer CT, Wiegering A: [Complete response after neoadjuvant therapy of rectal cancer: implications for surgery]. Chirurg 2022; 93: 144–51.","DOI":"10.1007\/s00104-021-01540-4"},{"key":"10.3238\/arztebl.m2022.0254_ref39","doi-asserted-by":"crossref","unstructured":"Gani C, Bonomo P, Zwirner K, et al.: Organ preservation in rectal cancer – challenges and future strategies. Clin Transl Radiat Oncol 2017; 3: 9–15.","DOI":"10.1016\/j.ctro.2017.02.002"},{"key":"10.3238\/arztebl.m2022.0254_ref40","unstructured":"ACO, AIO, ARO: Konsentierte Stellungnahme der ACO, der AIO und der ARO zum „watch and wait“-Konzept mit intendiertem Organerhalt bei Rektumkarzinomen des mittleren und unteren Drittels. \/www.aio- portal.de\/stellungnahmen.html?file=files\/content\/studien\/stellungnahmen\/2020\/ACO_AIO_ARO_Stellungnahme_10–2020.pdf&cid=141 (last accessed on 29 July 2022)."},{"key":"10.3238\/arztebl.m2022.0254_ref41","doi-asserted-by":"crossref","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A: Cancer statistics, 2022. CA Cancer J Clin 2022; 72: 7–33.","DOI":"10.3322\/caac.21708"},{"key":"10.3238\/arztebl.m2022.0254_ref42","doi-asserted-by":"crossref","unstructured":"Brenner H, Kloor M, Pox CP: Colorectal cancer. Lancet 2014; 383: 1490–502.","DOI":"10.1016\/S0140-6736(13)61649-9"},{"key":"10.3238\/arztebl.m2022.0254_ref43","doi-asserted-by":"crossref","unstructured":"Emrich K, Kraywinkel K: Epidemiologie des Rektumkarzinoms in Deutschland. Der Onkologe 2020; 26: 1085–94.","DOI":"10.1007\/s00761-020-00857-9"},{"key":"10.3238\/arztebl.m2022.0254_ref44","doi-asserted-by":"crossref","unstructured":"Sinicrope FA: Increasing incidence of early-onset colorectal cancer. N Engl J Med 2022; 386: 1547–58.","DOI":"10.1056\/NEJMra2200869"},{"key":"10.3238\/arztebl.m2022.0254_ref45","doi-asserted-by":"crossref","unstructured":"Mulder SA, Kranse R, Damhuis RA, et al.: Prevalence and prognosis of synchronous colorectal cancer: a Dutch population-based study. Cancer Epidemiol 2011; 35: 442–7.","DOI":"10.1016\/j.canep.2010.12.007"},{"key":"10.3238\/arztebl.m2022.0254_ref46","doi-asserted-by":"crossref","unstructured":"Chen HS, Sheen-Chen SM: Synchronous and „early“ metachronous colorectal adenocarcinoma: analysis of prognosis and current trends. Dis Colon Rectum 2000; 43: 1093–9.","DOI":"10.1007\/BF02236556"},{"key":"10.3238\/arztebl.m2022.0254_ref47","doi-asserted-by":"crossref","unstructured":"Nagtegaal ID, van de Velde CJ, van der Worp E, Kapiteijn E, Quirke P, van Krieken JH: Macroscopic evaluation of rectal cancer resection specimen: clinical significance of the pathologist in quality control. J Clin Oncol 2002; 20: 1729–34.","DOI":"10.1200\/JCO.2002.07.010"},{"key":"10.3238\/arztebl.m2022.0254_ref48","doi-asserted-by":"crossref","unstructured":"Quirke P, Steele R, Monson J, et al.: Effect of the plane of surgery achieved on local recurrence in patients with operable rectal cancer: a prospective study using data from the MRC CR07 and NCIC-CTG CO16 randomised clinical trial. Lancet 2009; 373: 821–8.","DOI":"10.1016\/S0140-6736(09)60485-2"},{"key":"10.3238\/arztebl.m2022.0254_ref49","doi-asserted-by":"crossref","unstructured":"Kitz J, Fokas E, Beissbarth T, et al.: Association of plane of total mesorectal excision with prognosis of rectal cancer: secondary analysis of the CAO\/ARO\/AIO-04 phase 3 randomized clinical trial. JAMA Surg 2018; 153: e181607.","DOI":"10.1001\/jamasurg.2018.1607"},{"key":"10.3238\/arztebl.m2022.0254_ref50","doi-asserted-by":"crossref","unstructured":"Folkesson J, Birgisson H, Pahlman L, Cedermark B, Glimelius B, Gunnarsson U: Swedish rectal cancer trial: long lasting benefits from radiotherapy on survival and local recurrence rate. J Clin Oncol 2005; 23: 5644–50.","DOI":"10.1200\/JCO.2005.08.144"},{"key":"10.3238\/arztebl.m2022.0254_ref51","doi-asserted-by":"crossref","unstructured":"van Gijn W, Marijnen CA, Nagtegaal ID, et al.: Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol 2011; 12: 575–82.","DOI":"10.1016\/S1470-2045(11)70097-3"},{"key":"10.3238\/arztebl.m2022.0254_ref52","doi-asserted-by":"crossref","unstructured":"Bujko K, Nowacki MP, Nasierowska-Guttmejer A, Michalski W, Bebenek M, Kryj M: Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg 2006; 93: 1215–23.","DOI":"10.1002\/bjs.5506"},{"key":"10.3238\/arztebl.m2022.0254_ref53","doi-asserted-by":"crossref","unstructured":"Ngan SY, Burmeister B, Fisher RJ, et al.: Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04. J Clin Oncol 2012; 30: 3827–33.","DOI":"10.1200\/JCO.2012.42.9597"},{"key":"10.3238\/arztebl.m2022.0254_ref54","doi-asserted-by":"crossref","unstructured":"Hofheinz RD, Wenz F, Post S, et al.: Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial. Lancet Oncol 2012; 13: 579–88.","DOI":"10.1016\/S1470-2045(12)70116-X"},{"key":"10.3238\/arztebl.m2022.0254_ref55","doi-asserted-by":"crossref","unstructured":"Erlandsson J, Holm T, Pettersson D, et al.: Optimal fractionation of preoperative radiotherapy and timing to surgery for rectal cancer (Stockholm III): a multicentre, randomised, non-blinded, phase 3, non-inferiority trial. Lancet Oncol 2017; 18: 336–46.","DOI":"10.1016\/S1470-2045(17)30086-4"},{"key":"10.3238\/arztebl.m2022.0254_ref56","doi-asserted-by":"crossref","unstructured":"Breugom AJ, Swets M, Bosset JF, et al.: Adjuvant chemotherapy after preoperative (chemo)radiotherapy and surgery for patients with rectal cancer: a systematic review and meta-analysis of individual patient data. Lancet Oncol 2015; 16: 200–7.","DOI":"10.1016\/S1470-2045(14)71199-4"},{"key":"10.3238\/arztebl.m2022.0254_ref57","doi-asserted-by":"crossref","unstructured":"Netter J, Douard R, Durdux C, Landi B, Berger A, Taieb J: Advances in management of adjuvant chemotherapy in rectal cancer: consequences for clinical practice. Clin Res Hepatol Gastroenterol 2016; 40: 546–52.","DOI":"10.1016\/j.clinre.2016.03.004"},{"key":"10.3238\/arztebl.m2022.0254_ref58","doi-asserted-by":"crossref","unstructured":"Carvalho C, Glynne-Jones R: Challenges behind proving efficacy of adjuvant chemotherapy after preoperative chemoradiation for rectal cancer. Lancet Oncol 2017; 18: e354–63.","DOI":"10.1016\/S1470-2045(17)30346-7"},{"key":"10.3238\/arztebl.m2022.0254_ref59","doi-asserted-by":"crossref","unstructured":"Glimelius B: Adjuvant chemotherapy in rectal cancer: state of the art and future perspectives. Curr Opin Oncol 2020; 32: 377–83.","DOI":"10.1097\/CCO.0000000000000641"},{"key":"10.3238\/arztebl.m2022.0254_ref60","doi-asserted-by":"crossref","unstructured":"Hong YS, Kim SY, Lee JS, et al.: Oxaliplatin-based adjuvant chemotherapy for rectal cancer after preoperative chemoradiotherapy (ADORE): long-term results of a randomized controlled trial. J Clin Oncol 2019; 37: 3111–23.","DOI":"10.1200\/JCO.19.00016"},{"key":"10.3238\/arztebl.m2022.0254_ref61","doi-asserted-by":"crossref","unstructured":"Beets-Tan RG, Beets GL: Local staging of rectal cancer: a review of imaging. J Magn Reson Imaging 2011; 33: 1012–9.","DOI":"10.1002\/jmri.22475"},{"key":"10.3238\/arztebl.m2022.0254_ref62","doi-asserted-by":"crossref","unstructured":"Al-Sukhni E, Milot L, Fruitman M, et al.: Diagnostic accuracy of MRI for assessment of T category, lymph node metastases, and circumferential resection margin involvement in patients with rectal cancer: a systematic review and meta-analysis. Ann Surg Oncol 2012; 19: 2212–23.","DOI":"10.1245\/s10434-011-2210-5"},{"key":"10.3238\/arztebl.m2022.0254_ref63","doi-asserted-by":"crossref","unstructured":"Brouwer NPM, Stijns RCH, Lemmens V, et al.: Clinical lymph node staging in colorectal cancer; a flip of the coin? Eur J Surg Oncol 2018; 44: 1241–6.","DOI":"10.1016\/j.ejso.2018.04.008"},{"key":"10.3238\/arztebl.m2022.0254_ref64","doi-asserted-by":"crossref","unstructured":"Peeters KC, van de Velde CJ, Leer JW, et al.: Late side effects of short-course preoperative radiotherapy combined with total mesorectal excision for rectal cancer: increased bowel dysfunction in irradiated patients—a Dutch colorectal cancer group study. J Clin Oncol 2005; 23: 6199–206.","DOI":"10.1200\/JCO.2005.14.779"},{"key":"10.3238\/arztebl.m2022.0254_ref65","doi-asserted-by":"crossref","unstructured":"Marijnen CA, van de Velde CJ, Putter H, et al.: Impact of short-term preoperative radiotherapy on health-related quality of life and sexual functioning in primary rectal cancer: report of a multicenter randomized trial. J Clin Oncol 2005; 23: 1847–58.","DOI":"10.1200\/JCO.2005.05.256"},{"key":"10.3238\/arztebl.m2022.0254_ref66","doi-asserted-by":"crossref","unstructured":"Stephens RJ, Thompson LC, Quirke P, et al.: Impact of short-course preoperative radiotherapy for rectal cancer on patients‘ quality of life: data from the Medical Research Council CR07\/National Cancer Institute of Canada Clinical Trials Group C016 randomized clinical trial. J Clin Oncol 2010; 28: 4233–9.","DOI":"10.1200\/JCO.2009.26.5264"},{"key":"10.3238\/arztebl.m2022.0254_ref67","doi-asserted-by":"crossref","unstructured":"Lange MM, van de Velde CJ: Urinary and sexual dysfunction after rectal cancer treatment. Nat Rev Urol 2011; 8: 51–7.","DOI":"10.1038\/nrurol.2010.206"},{"key":"10.3238\/arztebl.m2022.0254_ref68","doi-asserted-by":"crossref","unstructured":"Bryant CL, Lunniss PJ, Knowles CH, Thaha MA, Chan CL: Anterior resection syndrome. Lancet Oncol 2012; 13: e403–8.","DOI":"10.1016\/S1470-2045(12)70236-X"},{"key":"10.3238\/arztebl.m2022.0254_ref69","doi-asserted-by":"crossref","unstructured":"Emmertsen KJ, Laurberg S: Impact of bowel dysfunction on quality of life after sphincter-preserving resection for rectal cancer. Br J Surg 2013; 100: 1377–87.","DOI":"10.1002\/bjs.9223"},{"key":"10.3238\/arztebl.m2022.0254_ref70","doi-asserted-by":"crossref","unstructured":"Kreis ME, Ruppert R, Ptok H, et al.: Use of preoperative magnetic resonance imaging to select patients with rectal cancer for neoadjuvant chemoradiation—interim analysis of the German OCUM Trial (NCT01325649). J Gastrointest Surg 2016; 20: 25–32.","DOI":"10.1007\/s11605-015-3011-0"},{"key":"10.3238\/arztebl.m2022.0254_ref71","doi-asserted-by":"crossref","unstructured":"Ruppert R, Junginger T, Ptok H, et al.: Oncological outcome after MRI-based selection for neoadjuvant chemoradiotherapy in the OCUM Rectal Cancer Trial. Br J Surg 2018; 105: 1519–29.","DOI":"10.1002\/bjs.10879"},{"key":"10.3238\/arztebl.m2022.0254_ref72","doi-asserted-by":"crossref","unstructured":"Stelzner S, Ruppert R, Kube R, et al.: Selection of patients with rectal cancer for neoadjuvant therapy using pre-therapeutic MRI—Results from OCUM trial. Eur J Radiol 2022; 147: 110113.","DOI":"10.1016\/j.ejrad.2021.110113"},{"key":"10.3238\/arztebl.m2022.0254_ref73","doi-asserted-by":"crossref","unstructured":"Martellucci J: Low anterior resection syndrome: a treatment algorithm. Dis Colon Rectum 2016; 59: 79–82.","DOI":"10.1097\/DCR.0000000000000495"},{"key":"10.3238\/arztebl.m2022.0254_ref74","doi-asserted-by":"crossref","unstructured":"Jimenez-Gomez LM, Espin-Basany E, Marti-Gallostra M, Sanchez-Garcia JL, Vallribera-Valls F, Armengol-Carrasco M: Low anterior resection syndrome: a survey of the members of the American Society of Colon and Rectal Surgeons (ASCRS), the Spanish Association of Surgeons (AEC), and the Spanish Society of Coloproctology (AECP). Int J Colorectal Dis 2016; 31: 813–23.","DOI":"10.1007\/s00384-016-2511-z"},{"key":"10.3238\/arztebl.m2022.0254_ref75","doi-asserted-by":"crossref","unstructured":"van der Sande ME, Hupkens BJP, Berbee M, et al.: Impact of radiotherapy on anorectal function in patients with rectal cancer following a watch and wait programme. Radiother Oncol 2019; 132: 79–84.","DOI":"10.1016\/j.radonc.2018.11.017"},{"key":"10.3238\/arztebl.m2022.0254_ref76","doi-asserted-by":"crossref","unstructured":"Dossa F, Chesney TR, Acuna SA, Baxter NN: A watch-and-wait approach for locally advanced rectal cancer after a clinical complete response following neoadjuvant chemoradiation: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2017; 2: 501–13.","DOI":"10.1016\/S2468-1253(17)30074-2"},{"key":"10.3238\/arztebl.m2022.0254_ref77","doi-asserted-by":"crossref","unstructured":"Dattani M, Heald RJ, Goussous G, et al.: Oncological and survival outcomes in watch and wait patients with a clinical complete response after neoadjuvant chemoradiotherapy for rectal cancer: a systematic review and pooled analysis. Ann Surg 2018; 268: 955–67.","DOI":"10.1097\/SLA.0000000000002761"},{"key":"10.3238\/arztebl.m2022.0254_ref78","doi-asserted-by":"crossref","unstructured":"Kong JC, Guerra GR, Warrier SK, Ramsay RG, Heriot AG: Outcome and salvage surgery following „watch and wait“ for rectal cancer after neoadjuvant therapy: a systematic review. Dis Colon Rectum 2017; 60: 335–45.","DOI":"10.1097\/DCR.0000000000000754"},{"key":"10.3238\/arztebl.m2022.0254_ref79","doi-asserted-by":"crossref","unstructured":"Socha J, Kępka L, Michalski W, Paciorek K, Bujko K: The risk of distant metastases in rectal cancer managed by a watch-and-wait strategy—a systematic review and meta-analysis. Radiother Oncol 2020; 144: 1–6.","DOI":"10.1016\/j.radonc.2019.10.009"},{"key":"10.3238\/arztebl.m2022.0254_ref80","unstructured":"van der Valk MJM, Hilling DE, Bastiaannet E, et al.: Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry study. Lancet 2018; 391: 2537–45."},{"key":"10.3238\/arztebl.m2022.0254_ref81","doi-asserted-by":"crossref","unstructured":"Smith JJ, Strombom P, Chow OS, et al.: Assessment of a watch-and-wait strategy for rectal cancer in patients with a complete response after neoadjuvant therapy. JAMA Oncol 2019; 5: e185896.","DOI":"10.1001\/jamaoncol.2018.5896"},{"key":"10.3238\/arztebl.m2022.0254_ref82","doi-asserted-by":"crossref","unstructured":"Nagtegaal ID, Glynne-Jones R: How to measure tumour response in rectal cancer? An explanation of discrepancies and suggestions for improvement. Cancer Treat Rev 2020; 84: 101964.","DOI":"10.1016\/j.ctrv.2020.101964"},{"key":"10.3238\/arztebl.m2022.0254_ref83","doi-asserted-by":"crossref","unstructured":"Grade M, Wolff HA, Gaedcke J, Ghadimi BM: The molecular basis of chemoradiosensitivity in rectal cancer: implications for personalized therapies. Langenbeck’s Arch Surg 2012; 397: 543–55.","DOI":"10.1007\/s00423-012-0929-5"},{"key":"10.3238\/arztebl.m2022.0254_ref84","doi-asserted-by":"crossref","unstructured":"Ryan JE, Warrier SK, Lynch AC, Ramsay RG, Phillips WA, Heriot AG: Predicting pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a systematic review. Colorectal Dis 2016; 18: 234–46.","DOI":"10.1111\/codi.13207"},{"key":"10.3238\/arztebl.m2022.0254_ref85","doi-asserted-by":"crossref","unstructured":"Buckley AM, Lynam-Lennon N, O‘Neill H, O‘Sullivan J: Targeting hallmarks of cancer to enhance radiosensitivity in gastrointestinal cancers. Nat Rev Gastroenterol Hepatol 2020; 17: 298–313.","DOI":"10.1038\/s41575-019-0247-2"},{"key":"10.3238\/arztebl.m2022.0254_ref86","doi-asserted-by":"crossref","unstructured":"Alkan A, Hofving T, Angenete E, Yrlid U: Biomarkers and cell-based models to predict the outcome of neoadjuvant therapy for rectal cancer patients. Biomark Res 2021; 9: 60.","DOI":"10.1186\/s40364-021-00313-9"},{"key":"10.3238\/arztebl.m2022.0254_ref87","doi-asserted-by":"crossref","unstructured":"Kang SB, Park JW, Jeong SY, et al.: Open versus laparoscopic surgery for mid or low rectal cancer after neoadjuvant chemoradiotherapy (COREAN trial): short-term outcomes of an open-label randomised controlled trial. Lancet Oncol 2010; 11: 637–45.","DOI":"10.1016\/S1470-2045(10)70131-5"},{"key":"10.3238\/arztebl.m2022.0254_ref88","doi-asserted-by":"crossref","unstructured":"Jeong SY, Park JW, Nam BH, et al.: Open versus laparoscopic surgery for mid-rectal or low-rectal cancer after neoadjuvant chemoradiotherapy (COREAN trial): survival outcomes of an open-label, non-inferiority, randomised controlled trial. Lancet Oncol 2014; 15: 767–74.","DOI":"10.1016\/S1470-2045(14)70205-0"},{"key":"10.3238\/arztebl.m2022.0254_ref89","doi-asserted-by":"crossref","unstructured":"Park JW, Kang SB, Hao J, et al.: Open versus laparoscopic surgery for mid or low rectal cancer after neoadjuvant chemoradiotherapy (COREAN trial): 10-year follow-up of an open-label, non-inferiority, randomised controlled trial. Lancet Gastroenterol Hepatol 2021; 6: 569–77.","DOI":"10.1016\/S2468-1253(21)00094-7"},{"key":"10.3238\/arztebl.m2022.0254_ref90","doi-asserted-by":"crossref","unstructured":"van der Pas MH, Haglind E, Cuesta MA, et al.: Laparoscopic versus open surgery for rectal cancer (COLOR II): short-term outcomes of a randomised, phase 3 trial. Lancet Oncol 2013; 14: 210–8.","DOI":"10.1016\/S1470-2045(13)70016-0"},{"key":"10.3238\/arztebl.m2022.0254_ref91","doi-asserted-by":"crossref","unstructured":"Bonjer HJ, Deijen CL, Abis GA, et al.: A randomized trial of laparoscopic versus open surgery for rectal cancer. N Engl J Med 2015; 372: 1324–32.","DOI":"10.1056\/NEJMoa1414882"},{"key":"10.3238\/arztebl.m2022.0254_ref92","doi-asserted-by":"crossref","unstructured":"Andersson J, Abis G, Gellerstedt M, et al.: Patient-reported genitourinary dysfunction after laparoscopic and open rectal cancer surgery in a randomized trial (COLOR II). Br J Surg 2014; 101: 1272–9.","DOI":"10.1002\/bjs.9550"},{"key":"10.3238\/arztebl.m2022.0254_ref93","doi-asserted-by":"crossref","unstructured":"Andersson J, Angenete E, Gellerstedt M, et al.: Health-related quality of life after laparoscopic and open surgery for rectal cancer in a randomized trial. Br J Surg 2013; 100: 941–9.","DOI":"10.1002\/bjs.9144"},{"key":"10.3238\/arztebl.m2022.0254_ref94","doi-asserted-by":"crossref","unstructured":"Petersson J, Koedam TW, Bonjer HJ, et al.: Bowel obstruction and ventral hernia after laparoscopic versus open surgery for rectal cancer in a randomized trial (COLOR II). Ann Surg 2019; 269: 53–7.","DOI":"10.1097\/SLA.0000000000002790"},{"key":"10.3238\/arztebl.m2022.0254_ref95","doi-asserted-by":"crossref","unstructured":"Fleshman J, Branda M, Sargent DJ, et al.: Effect of laparoscopic-assisted resection vs open resection of stage II or III rectal cancer on pathologic outcomes: the ACOSOG Z6051 randomized clinical trial. JAMA 2015; 314: 1346–55.","DOI":"10.1001\/jama.2015.10529"},{"key":"10.3238\/arztebl.m2022.0254_ref96","doi-asserted-by":"crossref","unstructured":"Fleshman J, Branda ME, Sargent DJ, et al.: Disease-free survival and local recurrence for laparoscopic resection compared with open resection of stage II to III rectal cancer: follow-up results of the ACOSOG Z6051 randomized controlled trial. Ann Surg 2019; 269: 589–95.","DOI":"10.1097\/SLA.0000000000003002"},{"key":"10.3238\/arztebl.m2022.0254_ref97","doi-asserted-by":"crossref","unstructured":"Stevenson AR, Solomon MJ, Lumley JW, et al.: Effect of laparoscopic-assisted resection vs open resection on pathological outcomes in rectal cancer: the ALaCaRT randomized clinical trial. JAMA 2015; 314: 1356–63.","DOI":"10.1001\/jama.2015.12009"},{"key":"10.3238\/arztebl.m2022.0254_ref98","doi-asserted-by":"crossref","unstructured":"Stevenson ARL, Solomon MJ, Brown CSB, et al.: Disease-free survival and local recurrence after laparoscopic-assisted resection or open resection for rectal cancer: the australasian laparoscopic cancer of the rectum randomized clinical trial. Ann Surg 2019; 269: 596–602.","DOI":"10.1097\/SLA.0000000000003021"},{"key":"10.3238\/arztebl.m2022.0254_ref99","doi-asserted-by":"crossref","unstructured":"Jayne D, Pigazzi A, Marshall H, et al.: Effect of robotic-assisted vs conventional laparoscopic surgery on risk of conversion to open laparotomy among patients undergoing resection for rectal cancer: the ROLARR randomized clinical trial. JAMA 2017; 318: 1569–80.","DOI":"10.1001\/jama.2017.7219"},{"key":"10.3238\/arztebl.m2022.0254_ref100","doi-asserted-by":"crossref","unstructured":"Grade M, Flebbe H, Franke FS, et al.: Aktuelle M\u00f6glichkeiten und Evidenz roboterassistierter Eingriffe in der chirurgischen Onkologie. Der Onkologe 2019; 25: 14–27.","DOI":"10.1007\/s00761-019-0622-1"}],"container-title":["Deutsches \u00c4rzteblatt international"],"original-title":[],"link":[{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.m2022.0254","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T05:12:07Z","timestamp":1660108327000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.m2022.0254"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,22]]},"references-count":100,"URL":"https:\/\/doi.org\/10.3238\/arztebl.m2022.0254","relation":{},"ISSN":["1866-0452"],"issn-type":[{"value":"1866-0452","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,22]]}}}